首页> 美国卫生研究院文献>PLoS Neglected Tropical Diseases >A Heterologous Multiepitope DNA Prime/Recombinant Protein Boost Immunisation Strategy for the Development of an Antiserum against Micrurus corallinus (Coral Snake) Venom
【2h】

A Heterologous Multiepitope DNA Prime/Recombinant Protein Boost Immunisation Strategy for the Development of an Antiserum against Micrurus corallinus (Coral Snake) Venom

机译:异源多表位DNA初免/重组蛋白Boost免疫策略用于开发抗细叶珊瑚(珊瑚蛇)毒液的抗血清

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

BackgroundEnvenoming by coral snakes (Elapidae: Micrurus), although not abundant, represent a serious health threat in the Americas, especially because antivenoms are scarce. The development of adequate amounts of antielapidic serum for the treatment of accidents caused by snakes like Micrurus corallinus is a challenging task due to characteristics such as low venom yield, fossorial habit, relatively small sizes and ophiophagous diet. These features make it difficult to capture and keep these snakes in captivity for venom collection. Furthermore, there are reports of antivenom scarcity in USA, leading to an increase in morbidity and mortality, with patients needing to be intubated and ventilated while the toxin wears off. The development of an alternative method for the production of an antielapidic serum, with no need for snake collection and maintenance in captivity, would be a plausible solution for the antielapidic serum shortage.
机译:背景技术珊瑚蛇的毒蛇毒(Elapidae:Micrurus)尽管数量不多,但在美洲却构成了严重的健康威胁,特别是因为抗蛇毒血清缺乏。由于蛇毒产量低,窝窝习性,体型相对较小和食虫性饮食等特征,开发足够量的抗癫痫血清来治疗由蛇(如米氏珊瑚虫)引起的事故是一项艰巨的任务。这些特征使得难以捕获这些蛇并将其圈养以收集毒液。此外,有报道说美国抗蛇毒草素缺乏,导致发病率和死亡率增加,在毒素逐渐消失的情况下需要给患者插管和通气。无需蛇来收集和维持人工饲养能力,开发一种生产抗静电血清的替代方法将是解决抗静电血清不足的一种可行的解决方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号